An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy in treating Alzheimer’s disease. In votes, eight of the committee’s 11 members found Phase 3 EMERGE data did not provide “strong evidence” of efficacy, and seven members did not agree that aducanumab’s initial PRIME study, a Phase 1b trial, showed evidence supporting effectiveness (the other four members…
You must be logged in to read/download the full post.
The post FDA Committee Votes Do Not Support Aducanumab as Effective Treatment appeared first on BioNewsFeeds.